South Korea Covid 19 Clinical Trials Market Size & Outlook

The covid 19 clinical trials market in South Korea is expected to reach a projected revenue of US$ 70.6 million by 2030. A compound annual growth rate of 11% is expected of South Korea covid 19 clinical trials market from 2024 to 2030.
Revenue, 2023 (US$M)
$34.1
Forecast, 2030 (US$M)
$70.6
CAGR, 2024 - 2030
11%
Report Coverage
South Korea

South Korea covid 19 clinical trials market, 2018-2030 (US$M)

South

South Korea covid 19 clinical trials market highlights

  • The South Korea covid 19 clinical trials market generated a revenue of USD 34.1 million in 2023 and is expected to reach USD 70.6 million by 2030.
  • The South Korea market is expected to grow at a CAGR of 11% from 2024 to 2030.
  • In terms of segment, phase iii was the largest revenue generating phase in 2023.
  • Phase II is the most lucrative phase segment registering the fastest growth during the forecast period.


Covid 19 clinical trials market data book summary

Market revenue in 2023USD 34.1 million
Market revenue in 2030USD 70.6 million
Growth rate11% (CAGR from 2023 to 2030)
Largest segmentPhase iii
Fastest growing segmentPhase II
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III
Key market players worldwideInovio Pharmaceuticals Inc, AbbVie Inc, BioNTech SE ADR, Novavax Inc, Takeda Pharmaceutical Co Ltd


Other key industry trends

  • In terms of revenue, South Korea accounted for 0.6% of the global covid 19 clinical trials market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China covid 19 clinical trials market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 76.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

COVID 19 Clinical Trials Market Companies

Name Profile # Employees HQ Website

South Korea covid 19 clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid 19 clinical trials market will help companies and investors design strategic landscapes.


Phase iii was the largest segment with a revenue share of 55.72% in 2023. Horizon Databook has segmented the South Korea covid 19 clinical trials market based on phase i, phase ii, phase iii covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to South Korea covid 19 clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of South Korea covid 19 clinical trials market databook

  • Our clientele includes a mix of covid 19 clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the South Korea covid 19 clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into South Korea covid 19 clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

South Korea covid 19 clinical trials market size, by phase, 2018-2030 (US$M)

South Korea COVID 19 Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

South Korea covid 19 clinical trials market size, by phase, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more